Relapsed Diffuse large B-cell lymphoma NOS

Drug	Drug Name	Drug Description
DB16222	Loncastuximab tesirine	An antibody-drug conjugate used for the treatment of relapsed and refractory B-cell lymphomas.
DB12240	Polatuzumab vedotin	A CD79b antibody conjugate indicated to treat different types of large B-cell lymphoma.
DB11942	Selinexor	Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated...
DB15044	Tafasitamab	A CD19-directed cytolytic monoclonal antibody used in the treatment of B-cell malignancies.

Drug	Drug Name	Target	Type
DB16222	Loncastuximab tesirine	B-lymphocyte antigen CD19	target
DB16222	Loncastuximab tesirine	P-glycoprotein 1	transporter
DB16222	Loncastuximab tesirine	Cytochrome P450 3A4	enzyme
DB16222	Loncastuximab tesirine	Cytochrome P450 3A5	enzyme
DB12240	Polatuzumab vedotin	Cytochrome P450 3A4	enzyme
DB12240	Polatuzumab vedotin	B-cell antigen receptor complex-associated protein beta chain	target
DB12240	Polatuzumab vedotin	P-glycoprotein 1	transporter
DB12240	Polatuzumab vedotin	Cytochrome P450 3A5	enzyme
DB11942	Selinexor	Cytochrome P450 3A4	enzyme
DB11942	Selinexor	Solute carrier organic anion transporter family member 1B3	transporter
DB11942	Selinexor	Exportin-1	target
DB15044	Tafasitamab	B-lymphocyte antigen CD19	target

Drug	Drug Name	Phase	Status	Count